Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Nada M.S. Al-Saffar"'
Autor:
Martin O. Leach, Paul Workman, Juan C. Lacal, Ana Ramírez de Molina, Paul A. Clarke, Florence I. Raynaud, L. Elizabeth Jackson, Nada M.S. Al-Saffar
Supplementary Table 3 from The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57171b6ba6aa029eb847fe19ac3df84b
https://doi.org/10.1158/0008-5472.22382445.v1
https://doi.org/10.1158/0008-5472.22382445.v1
Autor:
Martin O. Leach, Paul Workman, Juan C. Lacal, Ana Ramírez de Molina, Paul A. Clarke, Florence I. Raynaud, L. Elizabeth Jackson, Nada M.S. Al-Saffar
Supplementary Table 2 from The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::635664e1056241b1a330faf0270617c7
https://doi.org/10.1158/0008-5472.22382448
https://doi.org/10.1158/0008-5472.22382448
Autor:
Martin O. Leach, Paul Workman, Juan C. Lacal, Ana Ramírez de Molina, Paul A. Clarke, Florence I. Raynaud, L. Elizabeth Jackson, Nada M.S. Al-Saffar
The phosphoinositide 3-kinase (PI3K) pathway is a major target for cancer drug development. PI-103 is an isoform-selective class I PI3K and mammalian target of rapamycin inhibitor. The aims of this work were as follows: first, to use magnetic resonan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d3b68b4a26986e068e7d0bcebc8f763
https://doi.org/10.1158/0008-5472.c.6500205
https://doi.org/10.1158/0008-5472.c.6500205
Autor:
Martin O. Leach, Paul Workman, Juan C. Lacal, Ana Ramírez de Molina, Paul A. Clarke, Florence I. Raynaud, L. Elizabeth Jackson, Nada M.S. Al-Saffar
Supplementary Table 4 from The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::554e298b9f32cbd68c162bcf67f3a8ef
https://doi.org/10.1158/0008-5472.22382442.v1
https://doi.org/10.1158/0008-5472.22382442.v1
Autor:
Martin O. Leach, Paul Workman, Juan C. Lacal, Ana Ramírez de Molina, Paul A. Clarke, Florence I. Raynaud, L. Elizabeth Jackson, Nada M.S. Al-Saffar
Supplementary Table 1 from The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f72d971a5e969b0f49653532d2f0816
https://doi.org/10.1158/0008-5472.22382451
https://doi.org/10.1158/0008-5472.22382451
Autor:
Helen Troy, Suzanne A. Eccles, Timothy A. Yap, Anne Christine Wong Te Fong, Jessica K.R. Boult, L. Elizabeth Jackson, Roberta Paravati, Yuen-Li Chung, Nada M.S. Al-Saffar, Simon P. Robinson, Sharon Gowan, Martin O. Leach
Publikováno v:
British Journal of Cancer
Background AKT is commonly overexpressed in tumours and plays an important role in the metabolic reprogramming of cancer. We have used magnetic resonance spectroscopy (MRS) to assess whether inhibition of AKT signalling would result in metabolic chan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e5aa1238554361539916180c143c197
http://europepmc.org/articles/PMC6219501
http://europepmc.org/articles/PMC6219501
Autor:
Juan Carlos Lacal, L. Elizabeth Jackson, Nada M.S. Al-Saffar, Ana Ramírez de Molina, Martin O. Leach, Florence I. Raynaud, Paul A. Clarke, Paul Workman
Publikováno v:
Cancer Research. 70:5507-5517
The phosphoinositide 3-kinase (PI3K) pathway is a major target for cancer drug development. PI-103 is an isoform-selective class I PI3K and mammalian target of rapamycin inhibitor. The aims of this work were as follows: first, to use magnetic resonan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2257f72963303fac12088a299c3a7b1a
https://doi.org/10.1158/0008-5472.can-09-4476
https://doi.org/10.1158/0008-5472.can-09-4476
Publikováno v:
British Journal of Cancer
Developing rational targeted cancer drugs requires the implementation of pharmacodynamic (PD), preferably non-invasive, biomarkers to aid response assessment and patient follow-up. Magnetic resonance spectroscopy (MRS) allows the non-invasive study o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04de1f90607ab2ad250853999ef3e6e7
http://europepmc.org/articles/PMC2813738
http://europepmc.org/articles/PMC2813738
Autor:
Sabrina M. Ronen, Mounia Beloueche-Babari, Martin O. Leach, L. Elizabeth Jackson, Nada M.S. Al-Saffar, Paul Workman
Publikováno v:
Cancer Research. 65:3356-3363
Several mitogen-activated protein kinase (MAPK) signaling inhibitors are currently undergoing clinical trial as part of novel mechanism-based anticancer treatment strategies. This study was aimed at detecting biomarkers of MAPK signaling inhibition i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::865f439aa4c7ea4ce3ab628c59f85647
https://doi.org/10.1158/10.1158/0008-5472.can-03-2981
https://doi.org/10.1158/10.1158/0008-5472.can-03-2981
Autor:
Lynley V. Marshall, Thomas R. Eykyn, Martin O. Leach, Alice Agliano, Geetha Balarajah, Chris Jones, Paul A. Clarke, L. Elizabeth Jackson, Nada M.S. Al-Saffar, Paul Workman, Andrew D.J. Pearson
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 8, p e103835 (2014)
PLoS ONE, Vol 9, Iss 8, p e103835 (2014)
The phosphoinositide 3-kinase (PI3K) pathway is believed to be of key importance in pediatric glioblastoma. Novel inhibitors of the PI3K pathway are being developed and are entering clinical trials. Our aim is to identify potential non-invasive bioma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9acd4dc80b3b8dbfe3295eff3a406c53
https://pubmed.ncbi.nlm.nih.gov/25084455
https://pubmed.ncbi.nlm.nih.gov/25084455